Q-omics provides the consensus-scored RPP38 profile across patient tissues and cancer cell-line models. RPP38 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPP38 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, RPP38 protein abundance shows 21,192 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where RPP38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPP38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPP38 survival associations across molecular data types. RPP38 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPP38 RNA expression–survival associations across cancer types. High RPP38 expression shows unfavorable associations in ACC, LIHC, KIRP, CESC and UVM, but favorable associations in LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPP38 RNA expression.
This table summarizes RPP38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RPP38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPP38 shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, STAD, HNSC and COAD. The KIRC box plot shows higher RPP38 RNA expression in tumor versus normal tissue (log2 FC = +0.398, t-test p < 0.001).
This table shows molecular features associated with RPP38 in patient tissues and cancer cell lines. In patient samples, RPP38 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPP38 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
